标签归档：cvt

CVT琼脂

发表于由
回复

上海金畔生物科技有限公司可以定制生产国产培养基，可以访问官网了解更多产品信息。
CVT琼脂

：
英文名称： CVT Agar
产品货号： JP8556
产品规格： 250g
150元
保质期： 三年
产品用途： 用于乳制品中嗜冷菌的计数
备  注：

产品介绍:

用途

用于乳制品中嗜冷菌计数。

原理

蛋白胨、酵母浸粉提供细菌生长所需的碳源、碳源及维生素，少量的葡萄糖可提供碳源促进细菌的快速生长，结晶紫可抑制一些非专性嗜冷的革兰氏阳性菌的生长，TTC为显色剂，细菌生长时可将TTC还原，菌落呈红色，琼脂为凝固剂。

用法

称取本品 23.5克，加热溶解1000ml蒸馏水中，121℃高压灭菌15分钟， 待冷至50℃倾入无菌平皿，备用。

注意：用涂布法计数；在20-25℃培养48-72小时，计数显红色菌落。

不同细菌在CVT琼脂上的生长特征

CVT琼脂微生物灵敏度试验:

按标签用法制备培养基，接种以下质控菌株，放置20-25℃需氧培养48-72小时。
注：回收率计算时，用TSA琼脂做对照培养基。

CVT琼脂原理及现象 https://www.hopebiol.com/asphtml/refere10837.htm

CVT琼脂相关产品:
产品货号 产品名称 产品规格 产品说明及用途
JP0101 平板计数琼脂（PCA）
Plate Count Agar		 250g 国际标准平板计数琼脂,含糖,用于细菌总数的测定（GB、SN标准）
JP0127 TTC营养琼脂
TTC Nutrient Agar		 250g 用于细菌总数测定
JP0109-11 牛肉膏蛋白胨琼脂培养基
Beef Extract Peptone Agar		 250g 用于一般细菌培养、转种、复壮和增菌等
JP0108 营养肉汤（NB）
Nutrient Broth		 250g 一般细菌培养,转种,复壮,增菌等（GB标准）
JP0109 营养琼脂（NA）
Nutrient Agar		 250g 细菌计数、不含糖，可作血琼脂基础和传代用(GB标准)
JPPT066 TGE肉汤(针筒装)
TGE Broth		 2ml*20支/盒 用于奶制品中滤膜法细菌总数计数
JP0132 2216E琼脂
2216E　Agar		 250g 用于海生细菌的培养和计数
JP0150 标准I号营养琼脂
Standard I Nutrient Agar		 250g 用于一般细菌的纯化培养
JP0160 胰化大豆坚固绿琼脂
Tryptic Soy Fast Green Agar		 250g 用于滤膜法中细菌总数测定
JP0162 m-TGE肉汤
m-TGE Broth		 250g 用于奶制品中滤膜法细菌总数计数
JP0166 水平板计数琼脂培养基
Water Plate Count Agar		 250g 用于水中微生物细菌总数计数
JP0167 R2A琼脂
R2A Agar		 250g 用于饮用水中细菌总数测定
JP8573 TGE琼脂
TGE Medium		 250g 用于细菌总数测定
JP0157 酵母粉琼脂（ISO6222）
Yeast Extract Agar 		250g 用于水中细菌总数的检测(ISO标准)
JP0101-3 平板计数琼脂（含麦芽提取物）
Plate Count Agar		 250g 用于菌落总数测定
JP0132-1 2216E液体培养基
2216E Liquid Medium		 250g 用于海生细菌的增菌培养
JP0101-5 嗜冷菌计数琼脂（乳平板计数琼脂）MPC
Psychrophilic bacteria count agar		 250g 用于乳制品中嗜冷菌菌落总数和需氧芽孢总数的测定
JP0109-4 NA培养基(含葡萄糖)
NA Medium		 250g 用于菌落总数测定
JP0101-4 MPC琼脂培养基
MPC Agar Medium		 250g 用于鲜奶菌落总数快速检测（阻抗法）
JP8520 接触皿培养基
contacts medium		 250g 用于生产环境的菌落总数检测
JP8756 平板计数肉汤（PCB） 250g 用于滤膜法计数菌落总数
JP0109-14 普通琼脂
Nutrient Agar		 250g 用于一般细菌培养、转种、增菌、复壮等
JP0101-4 MPC琼脂培养基
MPC Agar Medium		 250g 用于鲜奶菌落总数快速检测（阻抗法）
JP8502 SPYE肉汤
SPYE Broth		 100g 用于上机测定细菌总数
JP8533 Culture培养基(ISO标准)
Culture Medium		 250g 用于食品中细菌计数
JP8535 琼脂LT100
Agar LT100		 250g 用于食品中细菌计数
JP8837 TGY琼脂
TGY Agar		 250g 用于细菌的培养
JP0160 胰化大豆坚固绿琼脂
Tryptic Soy Fast Green Agar		 250g 用于滤膜法中细菌总数测定
JP9129 无碳源菌落计数培养基(ISO标准)
Plate Count Medium without Carbon Source		 250g 用于黄油、发酵奶和鲜奶酪中菌落总数的测定

生物活性分子抑制剂CVT-313(Synonyms: Cdk2 Inhibitor III)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

CVT-313 (Synonyms: Cdk2 Inhibitor III) 纯度: 99.45%

CVT-313 (Cdk2 Inhibitor III) 是一种有效的ATP-竞争性的选择性 CDK2 抑制剂，IC50 为 0.5 μM。CVT-313 可抑制 CDC5L 磷酸化。

CVT-313(Synonyms: Cdk2 Inhibitor III)

CVT-313 Chemical Structure

CAS No. : 199986-75-9

规格 价格 是否有货 数量
Free Sample (0.1-0.5 mg)   Apply now  
10 mM * 1 mL in DMSO ￥900 In-stock
5 mg ￥818 In-stock
10 mg ￥1228 In-stock
50 mg ￥4297 In-stock
100 mg   询价  
200 mg   询价  

* Please select Quantity before adding items.

CVT-313 相关产品

•相关化合物库:

  • Bioactive Compound Library Plus
  • Cell Cycle/DNA Damage Compound Library
  • Kinase Inhibitor Library
  • Anti-Cancer Compound Library
  • Anti-Aging Compound Library
  • Anti-Breast Cancer Compound Library
  • Anti-Pancreatic Cancer Compound Library
  • Anti-Blood Cancer Compound Library
  • Transcription Factor Targeted Library

生物活性

CVT-313 (Cdk2 Inhibitor III) is a potent, selective, reversible, and ATP-competitive inhibitor of CDK2 with IC50 of 0.5 μM. CVT-313 inhibits CDC5L phosphorylation[1].

IC50 & Target[1]

cdk2/cyclin A

0.5 μM (IC50)

Cdk1/cyclin B

4.2 μM (IC50)

Cdk4/cyclin D1

215 μM (IC50)

体外研究
(In Vitro)

CVT-313 (Cdk2 Inhibitor III) has been shown to inhibit other kinases, but at much higher IC50 values, i.e., CDK1 (IC50=4.2 μM), CDK4 D1 (IC50=215 μM), and MAPK/PKA/PKC (IC50>1.25 mM), compared to CDK2 (IC50=0.5 μM). CVT-313 has been shown to have profound effects on cell proliferation at concentrations of 5-20 μM[1]. CVT-313 is a potent CDK2 inhibitor, which is identified from a purine analog library with an IC50 of 0.5 μM in vitro. Inhibition is competitive with respect to ATP (Ki=95 nM), and selective CVT-313 has no effect on other, nonrelated ATP-dependent serine/threonine kinases. When added to CDK1 or CDK4, a 8.5- and 430-fold higher concentration of CVT-313 is required for half-maximal inhibition of the enzyme activity. Using normal and tumor human/murine cell lines, the effects of CVT-313 on cell proliferation is measured. The IC50 for growth inhibition ranged from 1.25 to 20 μM[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

400.47

Formula

C20H28N6O3
CAS 号

199986-75-9
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : ≥ 100 mg/mL (249.71 mM)

* “≥” means soluble, but saturation unknown.

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.4971 mL 12.4853 mL 24.9707 mL
5 mM 0.4994 mL 2.4971 mL 4.9941 mL
10 mM 0.2497 mL 1.2485 mL 2.4971 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (6.24 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (6.24 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂： 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (6.24 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (6.24 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
  • 3.

    请依序添加每种溶剂： 10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (6.24 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (6.24 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献

  • [1]. Graub R, et al. Cell cycle-dependent phosphorylation of human CDC5 regulates RNA processing. Cell Cycle. 2008 Jun 15;7(12):1795-803.

    [2]. Brooks EE, et al. CVT-313, a specific and potent inhibitor of CDK2 that prevents neointimal proliferation. J Biol Chem. 1997 Nov 14;272(46):29207-11.
Kinase Assay
[1]

For kinase assays, purified CDC5L(295-795)-His6 is mixed with [γ-32P]ATP, COS-7 cell extract, and incubated in 100 μL 20 mM HEPES, pH 7.5, 50 mM NaCl, 2 mM MnCl2, 10 mM MgCl2, 0.5% NP-40, 0.5 mM PMSF, 5 mM benzamidine hydrochloride, 5 mM NaF, 1 mM NaVO3 and the specific inhibitor at 30°C for 10 minutes. Cell extract as a source of kinase activity is prepared from subconfluent, serum-stimulated COS-7 cells lysed in 20 mM HEPES-NaOH, pH 7.5, 50 mM NaCl, 1% Triton X-100, 10% glycerol, protease and phosphotase inhibitors. Phosphorylated proteins are separated by electrophoresis in 15% polyacrylamide-SDS gels. Specific inhibitors included 20 μM staurosporine, 10 μM genistein, 1 μM CVT-313, 10 μM Rp-MB-cAMPS and 50 μM PD98059[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Assay
[2]

MRC-5 cells are grown in Dulbecco’s modified Eagle’s medium containing 5% fetal calf serum. CVT313 (0, 5, 10, 15 μM) is added to exponentially growing cells in tissue culture. Cell population is measured. Proliferation assays are carried out using the nonradioactive CellTiter 96 kit after 48-h exposure. For FACS analysis of DNA content, cells are trypsinized, fixed in 70% ice-cold ethanol, and treated with 0.1 mg/mL RNase A and 40 μg/mL propidium iodide for 1 h at 37°C[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献

  • [1]. Graub R, et al. Cell cycle-dependent phosphorylation of human CDC5 regulates RNA processing. Cell Cycle. 2008 Jun 15;7(12):1795-803.

    [2]. Brooks EE, et al. CVT-313, a specific and potent inhibitor of CDK2 that prevents neointimal proliferation. J Biol Chem. 1997 Nov 14;272(46):29207-11.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

生物活性分子抑制剂CVT-313(Synonyms: Cdk2 Inhibitor III)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。
CVT-313 (Synonyms: Cdk2 Inhibitor III) 纯度: 99.45%

CVT-313 (Cdk2 Inhibitor III) 是一种有效的ATP-竞争性的选择性 CDK2 抑制剂，IC50 为 0.5 μM。CVT-313 可抑制 CDC5L 磷酸化。

CVT-313(Synonyms: Cdk2 Inhibitor III)

CVT-313 Chemical Structure

CAS No. : 199986-75-9

规格 价格 是否有货 数量
Free Sample (0.1-0.5 mg)   Apply now  
10 mM * 1 mL in DMSO ￥900 In-stock
5 mg ￥818 In-stock
10 mg ￥1228 In-stock
50 mg ￥4297 In-stock
100 mg   询价  
200 mg   询价  

* Please select Quantity before adding items.

CVT-313 相关产品

•相关化合物库:

  • Bioactive Compound Library Plus
  • Cell Cycle/DNA Damage Compound Library
  • Kinase Inhibitor Library
  • Anti-Cancer Compound Library
  • Anti-Aging Compound Library
  • Anti-Breast Cancer Compound Library
  • Anti-Pancreatic Cancer Compound Library
  • Anti-Blood Cancer Compound Library
  • Transcription Factor Targeted Library

生物活性

CVT-313 (Cdk2 Inhibitor III) is a potent, selective, reversible, and ATP-competitive inhibitor of CDK2 with IC50 of 0.5 μM. CVT-313 inhibits CDC5L phosphorylation[1].

IC50 & Target[1]

cdk2/cyclin A

0.5 μM (IC50)

Cdk1/cyclin B

4.2 μM (IC50)

Cdk4/cyclin D1

215 μM (IC50)

体外研究
(In Vitro)

CVT-313 (Cdk2 Inhibitor III) has been shown to inhibit other kinases, but at much higher IC50 values, i.e., CDK1 (IC50=4.2 μM), CDK4 D1 (IC50=215 μM), and MAPK/PKA/PKC (IC50>1.25 mM), compared to CDK2 (IC50=0.5 μM). CVT-313 has been shown to have profound effects on cell proliferation at concentrations of 5-20 μM[1]. CVT-313 is a potent CDK2 inhibitor, which is identified from a purine analog library with an IC50 of 0.5 μM in vitro. Inhibition is competitive with respect to ATP (Ki=95 nM), and selective CVT-313 has no effect on other, nonrelated ATP-dependent serine/threonine kinases. When added to CDK1 or CDK4, a 8.5- and 430-fold higher concentration of CVT-313 is required for half-maximal inhibition of the enzyme activity. Using normal and tumor human/murine cell lines, the effects of CVT-313 on cell proliferation is measured. The IC50 for growth inhibition ranged from 1.25 to 20 μM[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

400.47

Formula

C20H28N6O3
CAS 号

199986-75-9
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : ≥ 100 mg/mL (249.71 mM)

* “≥” means soluble, but saturation unknown.

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.4971 mL 12.4853 mL 24.9707 mL
5 mM 0.4994 mL 2.4971 mL 4.9941 mL
10 mM 0.2497 mL 1.2485 mL 2.4971 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (6.24 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (6.24 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂： 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (6.24 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (6.24 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
  • 3.

    请依序添加每种溶剂： 10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (6.24 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (6.24 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献

  • [1]. Graub R, et al. Cell cycle-dependent phosphorylation of human CDC5 regulates RNA processing. Cell Cycle. 2008 Jun 15;7(12):1795-803.

    [2]. Brooks EE, et al. CVT-313, a specific and potent inhibitor of CDK2 that prevents neointimal proliferation. J Biol Chem. 1997 Nov 14;272(46):29207-11.
Kinase Assay
[1]

For kinase assays, purified CDC5L(295-795)-His6 is mixed with [γ-32P]ATP, COS-7 cell extract, and incubated in 100 μL 20 mM HEPES, pH 7.5, 50 mM NaCl, 2 mM MnCl2, 10 mM MgCl2, 0.5% NP-40, 0.5 mM PMSF, 5 mM benzamidine hydrochloride, 5 mM NaF, 1 mM NaVO3 and the specific inhibitor at 30°C for 10 minutes. Cell extract as a source of kinase activity is prepared from subconfluent, serum-stimulated COS-7 cells lysed in 20 mM HEPES-NaOH, pH 7.5, 50 mM NaCl, 1% Triton X-100, 10% glycerol, protease and phosphotase inhibitors. Phosphorylated proteins are separated by electrophoresis in 15% polyacrylamide-SDS gels. Specific inhibitors included 20 μM staurosporine, 10 μM genistein, 1 μM CVT-313, 10 μM Rp-MB-cAMPS and 50 μM PD98059[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Assay
[2]

MRC-5 cells are grown in Dulbecco’s modified Eagle’s medium containing 5% fetal calf serum. CVT313 (0, 5, 10, 15 μM) is added to exponentially growing cells in tissue culture. Cell population is measured. Proliferation assays are carried out using the nonradioactive CellTiter 96 kit after 48-h exposure. For FACS analysis of DNA content, cells are trypsinized, fixed in 70% ice-cold ethanol, and treated with 0.1 mg/mL RNase A and 40 μg/mL propidium iodide for 1 h at 37°C[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献

  • [1]. Graub R, et al. Cell cycle-dependent phosphorylation of human CDC5 regulates RNA processing. Cell Cycle. 2008 Jun 15;7(12):1795-803.

    [2]. Brooks EE, et al. CVT-313, a specific and potent inhibitor of CDK2 that prevents neointimal proliferation. J Biol Chem. 1997 Nov 14;272(46):29207-11.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Regadenoson-d3(Synonyms: CVT-3146-d3)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Regadenoson-d3 (Synonyms: CVT-3146-d3)

Regadenoson-d3 (CVT-3146-d3) 是 Regadenoson 的氘代物。Regadenoson (CVT-3146) 是一种有效的选择性 A2A 腺苷受体激动剂，对大鼠和猪腺苷 A2A 受体的 Ki 分别为 290 和 1120 nM。Regadenoson 对 A2A 受体的选择性高于人 A1 和 A2B 受体，其选择性是 A1 受体的 13 倍。Regadenoson 是一种血管扩张剂，它改变了血管扩张剂心肌灌注显像的前景。Re

Regadenoson-d3(Synonyms: CVT-3146-d3)

Regadenoson-d3 Chemical Structure

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

Regadenoson-d3 (CVT-3146-d3) is the deuterium labeled Regadenoson. Regadenoson (CVT-3146) is a potent and selective A2A adenosine receptor agonist, with Kis of 290 and 1120 nM for rat and pig adenosine A2A receptor, respectively. Regadenoson is selective for the adenosine A2A receptor over adenosine A1 and A2B receptors, and shows 13-fold selectivity over the human adenosine A1 receptor. Regadenoson is a vasodilator stress agent has shifted the landscape of vasodilator myocardial perfusion imaging. Regadenoson increases blood-brain barrier (BBB) permeability in rodents[1][2][3].

体外研究
(In Vitro)

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

393.37

Formula

C15H15D3N8O5
中文名称

瑞加德松 d3
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

    [2]. Jackson S, et al. The effect of regadenoson on the integrity of the human blood-brain barrier, a pilot study. J Neurooncol. 2017;132(3):513-519.

    [3]. Palle VP, et al. Structure-affinity relationships of the affinity of 2-pyrazolyl adenosine analogues for the adenosine A2A receptor. Bioorg Med Chem Lett. 2002;12(20):2935-2939.

    [4]. Golzar Y, et al. Regadenoson use in patients with chronic obstructive pulmonary disease: the state of current knowledge. Int J Chron Obstruct Pulmon Dis. 2014;9:129-137. Published 2014 Jan 22.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Regadenoson-d3(Synonyms: CVT-3146-d3)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Regadenoson-d3 (Synonyms: CVT-3146-d3)

Regadenoson-d3 (CVT-3146-d3) 是 Regadenoson 的氘代物。Regadenoson (CVT-3146) 是一种有效的选择性 A2A 腺苷受体激动剂，对大鼠和猪腺苷 A2A 受体的 Ki 分别为 290 和 1120 nM。Regadenoson 对 A2A 受体的选择性高于人 A1 和 A2B 受体，其选择性是 A1 受体的 13 倍。Regadenoson 是一种血管扩张剂，它改变了血管扩张剂心肌灌注显像的前景。Re

Regadenoson-d3(Synonyms: CVT-3146-d3)

Regadenoson-d3 Chemical Structure

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

Regadenoson-d3 (CVT-3146-d3) is the deuterium labeled Regadenoson. Regadenoson (CVT-3146) is a potent and selective A2A adenosine receptor agonist, with Kis of 290 and 1120 nM for rat and pig adenosine A2A receptor, respectively. Regadenoson is selective for the adenosine A2A receptor over adenosine A1 and A2B receptors, and shows 13-fold selectivity over the human adenosine A1 receptor. Regadenoson is a vasodilator stress agent has shifted the landscape of vasodilator myocardial perfusion imaging. Regadenoson increases blood-brain barrier (BBB) permeability in rodents[1][2][3].

体外研究
(In Vitro)

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

393.37

Formula

C15H15D3N8O5
中文名称

瑞加德松 d3
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

    [2]. Jackson S, et al. The effect of regadenoson on the integrity of the human blood-brain barrier, a pilot study. J Neurooncol. 2017;132(3):513-519.

    [3]. Palle VP, et al. Structure-affinity relationships of the affinity of 2-pyrazolyl adenosine analogues for the adenosine A2A receptor. Bioorg Med Chem Lett. 2002;12(20):2935-2939.

    [4]. Golzar Y, et al. Regadenoson use in patients with chronic obstructive pulmonary disease: the state of current knowledge. Int J Chron Obstruct Pulmon Dis. 2014;9:129-137. Published 2014 Jan 22.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Regadenoson-d3(Synonyms: CVT-3146-d3)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Regadenoson-d3 (Synonyms: CVT-3146-d3)

Regadenoson-d3 (CVT-3146-d3) 是 Regadenoson 的氘代物。Regadenoson (CVT-3146) 是一种有效的选择性 A2A 腺苷受体激动剂，对大鼠和猪腺苷 A2A 受体的 Ki 分别为 290 和 1120 nM。Regadenoson 对 A2A 受体的选择性高于人 A1 和 A2B 受体，其选择性是 A1 受体的 13 倍。Regadenoson 是一种血管扩张剂，它改变了血管扩张剂心肌灌注显像的前景。Re

Regadenoson-d3(Synonyms: CVT-3146-d3)

Regadenoson-d3 Chemical Structure

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

Regadenoson-d3 (CVT-3146-d3) is the deuterium labeled Regadenoson. Regadenoson (CVT-3146) is a potent and selective A2A adenosine receptor agonist, with Kis of 290 and 1120 nM for rat and pig adenosine A2A receptor, respectively. Regadenoson is selective for the adenosine A2A receptor over adenosine A1 and A2B receptors, and shows 13-fold selectivity over the human adenosine A1 receptor. Regadenoson is a vasodilator stress agent has shifted the landscape of vasodilator myocardial perfusion imaging. Regadenoson increases blood-brain barrier (BBB) permeability in rodents[1][2][3].

体外研究
(In Vitro)

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

393.37

Formula

C15H15D3N8O5
中文名称

瑞加德松 d3
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

    [2]. Jackson S, et al. The effect of regadenoson on the integrity of the human blood-brain barrier, a pilot study. J Neurooncol. 2017;132(3):513-519.

    [3]. Palle VP, et al. Structure-affinity relationships of the affinity of 2-pyrazolyl adenosine analogues for the adenosine A2A receptor. Bioorg Med Chem Lett. 2002;12(20):2935-2939.

    [4]. Golzar Y, et al. Regadenoson use in patients with chronic obstructive pulmonary disease: the state of current knowledge. Int J Chron Obstruct Pulmon Dis. 2014;9:129-137. Published 2014 Jan 22.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Ranolazine-d5(Synonyms: CVT 303-d5; RS 43285-003-d5)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Ranolazine-d5 (Synonyms: CVT 303-d5; RS 43285-003-d5)

Ranolazine-d5 (CVT 303-d5) 是 Ranolazine 的氘代物。Ranolazine (CVT 303) 是一种抗心绞痛和抗缺血剂，可通过抑制内向钠电流的后期作用 (对 INa 和 IKr 的 IC50 值分别为 6 μM 和 12 μM) 来发挥功效，而不会影响心率或血压。Ranolazine 还是脂肪酸氧化 (FAO) 的部分抑制剂。具有抗心绞痛作用。

Ranolazine-d5(Synonyms: CVT 303-d5; RS 43285-003-d5)

Ranolazine-d5 Chemical Structure

CAS No. : 1092804-87-9

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

Ranolazine-d5 (CVT 303-d5) is the deuterium labeled Ranolazine. Ranolazine (CVT 303) is an anti-angina drug that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP)[1][2]. Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor[3]. Antianginal agent.

体外研究
(In Vitro)

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

432.57

Formula

C24H28D5N3O4
CAS 号

1092804-87-9
中文名称

雷诺嗪 d5
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

    [2]. Keating GM. Ranolazine: a review of its use as add-on therapy in patients with chronic stable angina pectoris. Drugs. 2013 Jan;73(1):55-73.

    [3]. Wang WQ, et al. Antitorsadogenic effects of ({+/-})-N-(2,6-dimethyl-phenyl)-(4[2-hydroxy-3-(2-methoxyphenoxy)propyl]-1-piperazine (ranolazine) in anesthetized rabbits. J Pharmacol Exp Ther. 2008 Jun;325(3):875-81.

    [4]. Zacharowski K, et al. Ranolazine, a partial fatty acid oxidation inhibitor, reduces myocardial infarct size and cardiac troponin T release in the rat. Eur J Pharmacol. 2001 Apr 20;418(1-2):105-10.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Ranolazine-d5(Synonyms: CVT 303-d5; RS 43285-003-d5)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Ranolazine-d5 (Synonyms: CVT 303-d5; RS 43285-003-d5)

Ranolazine-d5 (CVT 303-d5) 是 Ranolazine 的氘代物。Ranolazine (CVT 303) 是一种抗心绞痛和抗缺血剂，可通过抑制内向钠电流的后期作用 (对 INa 和 IKr 的 IC50 值分别为 6 μM 和 12 μM) 来发挥功效，而不会影响心率或血压。Ranolazine 还是脂肪酸氧化 (FAO) 的部分抑制剂。具有抗心绞痛作用。

Ranolazine-d5(Synonyms: CVT 303-d5; RS 43285-003-d5)

Ranolazine-d5 Chemical Structure

CAS No. : 1092804-87-9

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

Ranolazine-d5 (CVT 303-d5) is the deuterium labeled Ranolazine. Ranolazine (CVT 303) is an anti-angina drug that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP)[1][2]. Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor[3]. Antianginal agent.

体外研究
(In Vitro)

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

432.57

Formula

C24H28D5N3O4
CAS 号

1092804-87-9
中文名称

雷诺嗪 d5
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

    [2]. Keating GM. Ranolazine: a review of its use as add-on therapy in patients with chronic stable angina pectoris. Drugs. 2013 Jan;73(1):55-73.

    [3]. Wang WQ, et al. Antitorsadogenic effects of ({+/-})-N-(2,6-dimethyl-phenyl)-(4[2-hydroxy-3-(2-methoxyphenoxy)propyl]-1-piperazine (ranolazine) in anesthetized rabbits. J Pharmacol Exp Ther. 2008 Jun;325(3):875-81.

    [4]. Zacharowski K, et al. Ranolazine, a partial fatty acid oxidation inhibitor, reduces myocardial infarct size and cardiac troponin T release in the rat. Eur J Pharmacol. 2001 Apr 20;418(1-2):105-10.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Ranolazine-d5(Synonyms: CVT 303-d5; RS 43285-003-d5)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Ranolazine-d5 (Synonyms: CVT 303-d5; RS 43285-003-d5)

Ranolazine-d5 (CVT 303-d5) 是 Ranolazine 的氘代物。Ranolazine (CVT 303) 是一种抗心绞痛和抗缺血剂，可通过抑制内向钠电流的后期作用 (对 INa 和 IKr 的 IC50 值分别为 6 μM 和 12 μM) 来发挥功效，而不会影响心率或血压。Ranolazine 还是脂肪酸氧化 (FAO) 的部分抑制剂。具有抗心绞痛作用。

Ranolazine-d5(Synonyms: CVT 303-d5; RS 43285-003-d5)

Ranolazine-d5 Chemical Structure

CAS No. : 1092804-87-9

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

Ranolazine-d5 (CVT 303-d5) is the deuterium labeled Ranolazine. Ranolazine (CVT 303) is an anti-angina drug that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP)[1][2]. Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor[3]. Antianginal agent.

体外研究
(In Vitro)

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

432.57

Formula

C24H28D5N3O4
CAS 号

1092804-87-9
中文名称

雷诺嗪 d5
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

    [2]. Keating GM. Ranolazine: a review of its use as add-on therapy in patients with chronic stable angina pectoris. Drugs. 2013 Jan;73(1):55-73.

    [3]. Wang WQ, et al. Antitorsadogenic effects of ({+/-})-N-(2,6-dimethyl-phenyl)-(4[2-hydroxy-3-(2-methoxyphenoxy)propyl]-1-piperazine (ranolazine) in anesthetized rabbits. J Pharmacol Exp Ther. 2008 Jun;325(3):875-81.

    [4]. Zacharowski K, et al. Ranolazine, a partial fatty acid oxidation inhibitor, reduces myocardial infarct size and cardiac troponin T release in the rat. Eur J Pharmacol. 2001 Apr 20;418(1-2):105-10.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

CVT-11127(Synonyms: GS-456332)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

CVT-11127 (Synonyms: GS-456332)

CVT-11127 是一种有效的 SCD 抑制剂。CVT-11127 诱导细胞凋亡 apoposis 并将细胞周期阻滞在 G1/S 期。 CVT-11127具有肺癌研究潜力。

CVT-11127(Synonyms: GS-456332)

CVT-11127 Chemical Structure

CAS No. : 1018674-83-3

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

CVT-11127 is a potent SCD inhibitor. CVT-11127 induces apoposis and arrests the cell cycle at the G1/S phase. CVT-11127 has the potential for the research of lung cancer[1].

IC50 & Target

SCD[1]
体外研究
(In Vitro)

CVT-11127 (1 µM, 48 h) shows antiproliferation activity in H460 cells[1].
CVT-11127 (1 µM, 48 h) decreases the the population of cells in S-phase by 75%[1].
CVT-11127 (1 µM, 48 h) induces apoposis in H460 cells[1].
CVT-11127 (1, 2 µM) inhibitors the SCD (stearoylCoA desaturase) activity in H460 cells[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay[1]

Cell Line: H460 cells
Concentration: 1 µM
Incubation Time: 48 h
Result: Showed antiproliferation activity.

Cell Cycle Analysis[1]

Cell Line: H460 cells
Concentration: 1 µM
Incubation Time: 48 h
Result: Decreased the the population of cells in S-phase by 75%.

Apoptosis Analysis[1]

Cell Line: H460 cells
Concentration: 1 µM
Incubation Time: 24 h
Result: Induced apoposis H460 cells.

分子量

512.39

Formula

C25H23Cl2N5O3
CAS 号

1018674-83-3
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Hess D,et al. Inhibition of stearoylCoA desaturase activity blocks cell cycle progression and induces programmed cell death in lung cancer cells. PLoS One. 2010; 5(6):e11394.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

CVT-11127(Synonyms: GS-456332)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

CVT-11127 (Synonyms: GS-456332)

CVT-11127 是一种有效的 SCD 抑制剂。CVT-11127 诱导细胞凋亡 apoposis 并将细胞周期阻滞在 G1/S 期。 CVT-11127具有肺癌研究潜力。

CVT-11127(Synonyms: GS-456332)

CVT-11127 Chemical Structure

CAS No. : 1018674-83-3

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

CVT-11127 is a potent SCD inhibitor. CVT-11127 induces apoposis and arrests the cell cycle at the G1/S phase. CVT-11127 has the potential for the research of lung cancer[1].

IC50 & Target

SCD[1]
体外研究
(In Vitro)

CVT-11127 (1 µM, 48 h) shows antiproliferation activity in H460 cells[1].
CVT-11127 (1 µM, 48 h) decreases the the population of cells in S-phase by 75%[1].
CVT-11127 (1 µM, 48 h) induces apoposis in H460 cells[1].
CVT-11127 (1, 2 µM) inhibitors the SCD (stearoylCoA desaturase) activity in H460 cells[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay[1]

Cell Line: H460 cells
Concentration: 1 µM
Incubation Time: 48 h
Result: Showed antiproliferation activity.

Cell Cycle Analysis[1]

Cell Line: H460 cells
Concentration: 1 µM
Incubation Time: 48 h
Result: Decreased the the population of cells in S-phase by 75%.

Apoptosis Analysis[1]

Cell Line: H460 cells
Concentration: 1 µM
Incubation Time: 24 h
Result: Induced apoposis H460 cells.

分子量

512.39

Formula

C25H23Cl2N5O3
CAS 号

1018674-83-3
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Hess D,et al. Inhibition of stearoylCoA desaturase activity blocks cell cycle progression and induces programmed cell death in lung cancer cells. PLoS One. 2010; 5(6):e11394.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

CVT-11127(Synonyms: GS-456332)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

CVT-11127 (Synonyms: GS-456332)

CVT-11127 是一种有效的 SCD 抑制剂。CVT-11127 诱导细胞凋亡 apoposis 并将细胞周期阻滞在 G1/S 期。 CVT-11127具有肺癌研究潜力。

CVT-11127(Synonyms: GS-456332)

CVT-11127 Chemical Structure

CAS No. : 1018674-83-3

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

CVT-11127 is a potent SCD inhibitor. CVT-11127 induces apoposis and arrests the cell cycle at the G1/S phase. CVT-11127 has the potential for the research of lung cancer[1].

IC50 & Target

SCD[1]
体外研究
(In Vitro)

CVT-11127 (1 µM, 48 h) shows antiproliferation activity in H460 cells[1].
CVT-11127 (1 µM, 48 h) decreases the the population of cells in S-phase by 75%[1].
CVT-11127 (1 µM, 48 h) induces apoposis in H460 cells[1].
CVT-11127 (1, 2 µM) inhibitors the SCD (stearoylCoA desaturase) activity in H460 cells[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay[1]

Cell Line: H460 cells
Concentration: 1 µM
Incubation Time: 48 h
Result: Showed antiproliferation activity.

Cell Cycle Analysis[1]

Cell Line: H460 cells
Concentration: 1 µM
Incubation Time: 48 h
Result: Decreased the the population of cells in S-phase by 75%.

Apoptosis Analysis[1]

Cell Line: H460 cells
Concentration: 1 µM
Incubation Time: 24 h
Result: Induced apoposis H460 cells.

分子量

512.39

Formula

C25H23Cl2N5O3
CAS 号

1018674-83-3
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Hess D,et al. Inhibition of stearoylCoA desaturase activity blocks cell cycle progression and induces programmed cell death in lung cancer cells. PLoS One. 2010; 5(6):e11394.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Ranolazine(Synonyms: 雷诺嗪; CVT 303; RS 43285-003)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Ranolazine (Synonyms: 雷诺嗪; CVT 303; RS 43285-003) 纯度: 99.72%

Ranolazine (CVT 303) 是一种抗心绞痛和抗缺血剂，可通过抑制内向钠电流的后期作用 (对 INa 和 IKr 的 IC50 值分别为 6 μM 和 12 μM) 来发挥功效，而不会影响心率或血压。Ranolazine 还是脂肪酸氧化 (FAO) 的部分抑制剂。具有抗心绞痛作用。

Ranolazine(Synonyms: 雷诺嗪; CVT 303; RS 43285-003)

Ranolazine Chemical Structure

CAS No. : 95635-55-5

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ￥972 In-stock
100 mg ￥884 In-stock
200 mg ￥1350 In-stock
500 mg ￥2200 In-stock
1 g   询价  
5 g   询价  

* Please select Quantity before adding items.

Ranolazine 相关产品

•相关化合物库:

  • Drug Repurposing Compound Library Plus
  • FDA-Approved Drug Library Plus
  • FDA-Approved Drug Library Mini
  • Bioactive Compound Library Plus
  • Membrane Transporter/Ion Channel Compound Library
  • Neuronal Signaling Compound Library
  • FDA-Approved Drug Library
  • Anti-Cancer Compound Library
  • Drug Repurposing Compound Library
  • Anti-Cardiovascular Disease Compound Library
  • Anti-COVID-19 Compound Library
  • Orally Active Compound Library
  • FDA Approved & Pharmacopeial Drug Library
  • Neuroprotective Compound Library
  • Drug-Induced Liver Injury (DILI) Compound Library
  • Rare Diseases Drug Library

生物活性

Ranolazine (CVT 303) is an anti-angina drug that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP)[1][2]. Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor[3]. Antianginal agent.

IC50 & Target

IC50: 6 μM (INa), 12 μM (IKr)[1]
体内研究
(In Vivo)

Ranolazine (Bolus injection 10 mg/kg and infusion 9.6 mg/kg/h; bolus injection; for 145 minutes; male Wistar rats) treatment significantly reduces infarct size and cardiac troponin T release in rats subjected to left anterior descending coronary artery occlusion-reperfusion[3].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male Wistar rats (240-350 g)[3]
Dosage: Bolus injection 10 mg/kg and infusion (9.6 mg/kg/h)
Administration: Bolus injection; for 145 minutes
Result: Significantly reduced infarct size and cardiac troponin T release in rats subjected to left anterior descending coronary artery occlusion-reperfusion.

Clinical Trial

分子量

427.54

Formula

C24H33N3O4
CAS 号

95635-55-5
中文名称

雷诺嗪
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 125 mg/mL (292.37 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.3390 mL 11.6948 mL 23.3896 mL
5 mM 0.4678 mL 2.3390 mL 4.6779 mL
10 mM 0.2339 mL 1.1695 mL 2.3390 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.08 mg/mL (4.87 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (4.87 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂： 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.08 mg/mL (4.87 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (4.87 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
  • 3.

    请依序添加每种溶剂： 10% DMSO    90% corn oil

    Solubility: ≥ 2.08 mg/mL (4.87 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (4.87 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献

  • [1]. Keating GM. Ranolazine: a review of its use as add-on therapy in patients with chronic stable angina pectoris. Drugs. 2013 Jan;73(1):55-73.

    [2]. Wang WQ, et al. Antitorsadogenic effects of ({+/-})-N-(2,6-dimethyl-phenyl)-(4[2-hydroxy-3-(2-methoxyphenoxy)propyl]-1-piperazine (ranolazine) in anesthetized rabbits. J Pharmacol Exp Ther. 2008 Jun;325(3):875-81.

    [3]. Zacharowski K, et al. Ranolazine, a partial fatty acid oxidation inhibitor, reduces myocardial infarct size and cardiac troponin T release in the rat. Eur J Pharmacol. 2001 Apr 20;418(1-2):105-10.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Ranolazine dihydrochloride(Synonyms: 盐酸雷诺嗪; CVT 303 dihydrochloride; RS 43285)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Ranolazine dihydrochloride (Synonyms: 盐酸雷诺嗪; CVT 303 dihydrochloride; RS 43285) 纯度: 99.79%

Ranolazine dihydrochloride (CVT 303 dihydrochloride) 是一种抗心绞痛和抗缺血剂，可通过抑制内向钠电流的后期作用 (对 INa 和 IKr 的 IC50 值分别为 6 μM 和 12 μM) 来发挥功效，而不会影响心率或血压。Ranolazine dihydrochloride 还是脂肪酸氧化的部分抑制剂。

Ranolazine dihydrochloride(Synonyms: 盐酸雷诺嗪; CVT 303 dihydrochloride; RS 43285)

Ranolazine dihydrochloride Chemical Structure

CAS No. : 95635-56-6

规格 价格 是否有货 数量
Free Sample (0.1-0.5 mg)   Apply now  
10 mM * 1 mL in DMSO ￥737 In-stock
100 mg ￥670 In-stock
200 mg ￥1100 In-stock
500 mg ￥1600 In-stock
1 g ￥2000 In-stock
5 g ￥6000 In-stock
10 g   询价  
50 g   询价  

* Please select Quantity before adding items.

Ranolazine dihydrochloride 相关产品

•相关化合物库:

  • Drug Repurposing Compound Library Plus
  • FDA-Approved Drug Library Plus
  • FDA-Approved Drug Library Mini
  • Bioactive Compound Library Plus
  • Membrane Transporter/Ion Channel Compound Library
  • Neuronal Signaling Compound Library
  • FDA-Approved Drug Library
  • Anti-Cancer Compound Library
  • Autophagy Compound Library
  • Drug Repurposing Compound Library
  • Anti-Cardiovascular Disease Compound Library
  • Orally Active Compound Library
  • FDA Approved & Pharmacopeial Drug Library
  • Neuroprotective Compound Library
  • Drug-Induced Liver Injury (DILI) Compound Library
  • Rare Diseases Drug Library

生物活性

Ranolazine dihydrochloride (CVT 303 dihydrochloride) is an anti-angina drug that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP)[1][2]. Ranolazine dihydrochloride is also a partial fatty acid oxidation inhibitor[3].

IC50 & Target

IC50: 6 μM (INa), 12 μM (IKr)[1]
体内研究
(In Vivo)

Ranolazine (Bolus injection 10 mg/kg and infusion 9.6 mg/kg/h; bolus injection; for 145 minutes; male Wistar rats) treatment significantly reduces infarct size and cardiac troponin T release in rats subjected to left anterior descending coronary artery occlusion-reperfusion[3].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male Wistar rats (240-350 g)[3]
Dosage: Bolus injection 10 mg/kg and infusion (9.6 mg/kg/h)
Administration: Bolus injection; for 145 minutes
Result: Significantly reduced infarct size and cardiac troponin T release in rats subjected to left anterior descending coronary artery occlusion-reperfusion.

Clinical Trial

分子量

500.46

Formula

C24H35Cl2N3O4
CAS 号

95635-56-6
中文名称

盐酸雷诺嗪
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
溶解性数据
In Vitro: 

DMSO : ≥ 50 mg/mL (99.91 mM)

H2O : ≥ 50 mg/mL (99.91 mM)

* “≥” means soluble, but saturation unknown.

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.9982 mL 9.9908 mL 19.9816 mL
5 mM 0.3996 mL 1.9982 mL 3.9963 mL
10 mM 0.1998 mL 0.9991 mL 1.9982 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： PBS

    Solubility: 13000 mg/mL (25976.10 mM); Clear solution; Need ultrasonic

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献

  • [1]. Keating GM. Ranolazine: A Review of Its Use as Add-On Therapy in Patients with Chronic Stable Angina Pectoris. Drugs. 2013 Jan;73(1):55-73.

    [2]. Wang WQ, Robertson C, Dhalla AK, Belardinelli L. Antitorsadogenic effects of ({+/-})-N-(2,6-dimethyl-phenyl)-(4[2-hydroxy-3-(2-methoxyphenoxy)propyl]-1-piperazine (ranolazine) in anesthetized rabbits. J Pharmacol Exp Ther. 2008 Jun;325(3):875-81. doi: 10.1124/jpet.108.137729. Epub 2008 Mar 5.

    [3]. Zacharowski K, Blackburn B, Thiemermann C. Ranolazine, a partial fatty acid oxidation inhibitor, reduces myocardial infarct size and cardiac troponin T release in the rat. Eur J Pharmacol. 2001 Apr 20;418(1-2):105-10.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Regadenoson(Synonyms: 瑞加德松; CVT-3146)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Regadenoson (Synonyms: 瑞加德松; CVT-3146) 纯度: 99.59%

Regadenoson (CVT-3146) 是一种有效的选择性 A2A 腺苷受体激动剂，对大鼠和猪腺苷 A2A 受体的 Ki 分别为 290 和 1120 nM。Regadenoson 对 A2A 受体的选择性高于人 A1 和 A2B 受体，其选择性是 A1 受体的 13 倍。Regadenoson 是一种血管扩张剂，它改变了血管扩张剂心肌灌注显像的前景。Regadenoson 增加了啮齿动物血脑屏障 (BBB) 的通透性。

Regadenoson(Synonyms: 瑞加德松; CVT-3146)

Regadenoson Chemical Structure

CAS No. : 313348-27-5

规格 价格 是否有货 数量
Free Sample (0.1-0.5 mg)   Apply now  
10 mM * 1 mL in DMSO ￥850 In-stock
2 mg ￥600 In-stock
5 mg ￥990 In-stock
10 mg ￥1700 In-stock
25 mg ￥3100 In-stock
50 mg ￥4650 In-stock
100 mg   询价  
200 mg   询价  

* Please select Quantity before adding items.

Regadenoson 相关产品

•相关化合物库:

  • Drug Repurposing Compound Library Plus
  • FDA-Approved Drug Library Plus
  • FDA-Approved Drug Library Mini
  • Bioactive Compound Library Plus
  • GPCR/G Protein Compound Library
  • FDA-Approved Drug Library
  • Anti-Cancer Compound Library
  • Small Molecule Immuno-Oncology Compound Library
  • Drug Repurposing Compound Library
  • Nucleotide Compound Library
  • Anti-Cardiovascular Disease Compound Library
  • Anti-COVID-19 Compound Library
  • Neurotransmitter Receptor Compound Library
  • FDA Approved & Pharmacopeial Drug Library
  • Neuroprotective Compound Library
  • Drug-Induced Liver Injury (DILI) Compound Library
  • Rare Diseases Drug Library

生物活性

Regadenoson (CVT-3146) is a potent and selective A2A adenosine receptor agonist, with Kis of 290 and 1120 nM for rat and pig adenosine A2A receptor, respectively. Regadenoson is selective for the adenosine A2A receptor over adenosine A1 and A2B receptors, and shows 13-fold selectivity over the human adenosine A1 receptor. Regadenoson is a vasodilator stress agent has shifted the landscape of vasodilator myocardial perfusion imaging. Regadenoson increases blood-brain barrier (BBB) permeability in rodents[1][2][3].

Clinical Trial

分子量

390.35

Formula

C15H18N8O5
CAS 号

313348-27-5
中文名称

瑞加德松；类伽腺苷
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 50 mg/mL (128.09 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.5618 mL 12.8090 mL 25.6180 mL
5 mM 0.5124 mL 2.5618 mL 5.1236 mL
10 mM 0.2562 mL 1.2809 mL 2.5618 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (6.40 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (6.40 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂： 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (6.40 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (6.40 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
  • 3.

    请依序添加每种溶剂： 10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (6.40 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (6.40 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献

  • [1]. Palle VP, et al. Structure-affinity relationships of the affinity of 2-pyrazolyl adenosine analogues for the adenosine A2A receptor. Bioorg Med Chem Lett. 2002;12(20):2935-2939.

    [2]. Golzar Y, et al. Regadenoson use in patients with chronic obstructive pulmonary disease: the state of current knowledge. Int J Chron Obstruct Pulmon Dis. 2014;9:129-137. Published 2014 Jan 22.

    [3]. Jackson S, et al. The effect of regadenoson on the integrity of the human blood-brain barrier, a pilot study. J Neurooncol. 2017;132(3):513-519.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务